CLINICAL TRIALS PROFILE FOR CLOBEX
✉ Email this page to a colleague
All Clinical Trials for clobex
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00400725 ↗ | Maintenance Effect of Clobex Shampoo on Subjects With Moderate to Severe Scalp Psoriasis | Completed | Galderma | Phase 3 | 2006-09-01 | The objective of the study is to assess the maintenance effect on scalp psoriasis of Clobex® Shampoo 0.05% when used twice weekly. |
| NCT00400725 ↗ | Maintenance Effect of Clobex Shampoo on Subjects With Moderate to Severe Scalp Psoriasis | Completed | Galderma R&D | Phase 3 | 2006-09-01 | The objective of the study is to assess the maintenance effect on scalp psoriasis of Clobex® Shampoo 0.05% when used twice weekly. |
| NCT00436540 ↗ | A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam | Completed | Galderma Laboratories, L.P. | Phase 4 | 2006-03-01 | The primary objective of this study is to evaluate the efficacy and safety of clobetasol propionate 0.05% (Clobex®) spray compared to clobetasol propionate 0.05% (Olux®) foam. |
| NCT00437216 ↗ | Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis | Completed | Galderma Laboratories, L.P. | 2006-02-01 | Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents. | |
| NCT00437255 ↗ | Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis | Completed | Galderma Laboratories, L.P. | Phase 4 | 2006-08-01 | Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment. |
| NCT00438399 ↗ | Subject Preference for Scalp Psoriasis Treatment | Completed | Galderma | Phase 3 | 2007-02-01 | The scalp is one of the most common affected sites in psoriatic patients as 79% of them have scalp involvement.It has also a psychological aspect with 31% of patients with scalp psoriasis indicating distress. Topical agents remain the mainstay of treatment for scalp psoriasis. However, they are not always ideal because they might be inconvenient and messy to use, stain or damage hair. The test shampoo, Clobetasol propionate Shampoo 0.05% (marketed in the USA under the tradename of Clobex®) was developed to provide the strongest available corticosteroid as a short-contact therapy in order to improve the chances of it being effective and reduce the potential for traditional side-effects. The objective of this study is to compare subject's overall preference between Clobetasol propionate shampoo 0.05% and three other topical corticosteroids in the treatment of moderate to severe scalp psoriasis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for clobex
Condition Name
Clinical Trial Locations for clobex
Trials by Country
Clinical Trial Progress for clobex
Clinical Trial Phase
Clinical Trial Sponsors for clobex
Sponsor Name
